Method To Treat Numerous Types Of Cancer Using Small Molecule Inhibitors
Background:
The National Cancer Institute's Urologic Oncology Branch is seeking
statements of capability or interest from parties interested in
collaborative research to further develop, evaluate, or
commercialize small molecule inhibitors of the c-Met signaling
pathway.
Technology:
A key defect in many types of cancer is unregulated activation of
an enzyme known as c-Met. Aberrant c Met signaling is
documented in a wide variety of cancers and occurs via several
mechanisms. This invention describes novel small molecule
inhibitors of c-Met signaling. The small molecules
selectively bind to c-Met and have an IC50 in the micromolar range.
The small molecules belong to two different families. One
family of small molecules reduces the level of c Met expression via
receptor down-regulation and blocks ATP binding. The other
family of small molecules block ATP binding without inducing
receptor down-regulation.
Further R&D Needed:
- Preclinical cell-free and cell-based SAR studies to improve
selectivity and potency.
- Preclinical biological studies in cultured cell and animal
models.
- Preclinical PK and toxicological studies in animals.
R&D Status: Pre-clinical
development.
IP Status:
U.S. Provisional Application No. 61/041,523 filed 01 April 2008
Value Proposition:
- Ability to develop therapeutics for numerous types of cancers
associated with aberrant c-Met signaling including bladder, breast,
cervical, colorectal, endometrial, esophageal, gastric, head and
neck, kidney, liver, lung, nasopharyngeal, ovarian, pancreatic,
prostate and thyroid cancers.
- Ability to develop therapeutics for hematological malignancies
such as acute myelogenous leukemia, adult T cell leukemia, chronic
myeloid leukemia, lymphomas and multiple myeloma
Contact Information:
John D. Hewes, Ph.D.
NCI Technology Transfer Center
Tel: 301-435-3121
Email: hewesj@mail.nih.gov
Please reference advertisement #724